Scientists believe combining navitoclax with ruxolitinib might help individuals with myelofibrosis. During this trial half the people have navitoclax and ruxolitinib. The opposite 50 % have ruxolitinib and a dummy drug (placebo ). have intermediate two or high danger myelofibrosis and also have not had a JAK2 inhibitor drug which https://heinrichb554ugr3.wikibuysell.com/user